Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dyslipidemias Clear all
Recruiting No phase listed Observational

Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions

NCT06676046
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease

NCT04195932
View directory record Official record
Conditions
Heart Diseases
Interventions
Exercise training
Other
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1998
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

NCT00680017
View directory record Official record
Conditions
Dyslipidemia, Kidney Disease
Interventions
ABT-335 plus rosuvastatin, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
102
States / cities
Birmingham, Alabama • Huntsville, Alabama • Madison, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Chronic Effects of Freeze-Dried Strawberry Beverage on Cardiovascular Risk Factors

NCT01883401
View directory record Official record
Conditions
Dyslipidemia, Obesity
Interventions
Freeze-dried strawberries, Dietary fiber
Dietary Supplement
Lead sponsor
Oklahoma State University
Other
Eligibility
19 Years to 72 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers

NCT01148004
View directory record Official record
Conditions
HIV, Fenofibrate, Protease Inhibitors, Hypertriglyceridemia, Glucuronosyltransferase
Interventions
Fenofibrate, Ritonavir, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 19, 2026, 11:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fenofibrate and Pharmacogenetic Impact in Dyslipidemia

NCT00613613
View directory record Official record
Conditions
Dyslipidemia
Interventions
fenofibrate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 2 Interventional

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

NCT00237640
View directory record Official record
Conditions
Diabetes Mellitus, Adult Onset
Interventions
Cinnamon or placebo 500 mg capsule twice daily
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

NCT07316608
View directory record Official record
Conditions
Healthy Participants
Interventions
Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 19, 2026, 11:21 AM EDT
Enrolling by invitation Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

NCT07102511
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
lerodalcibep 300 mg Monthly SC
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Colchicine Tablets

NCT01021020
View directory record Official record
Conditions
Healthy
Interventions
Colchicine, Colchicine/Probenecid
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

NCT02944383
View directory record Official record
Conditions
Severe Hypertriglyceridemia, Mixed Dyslipidaemia
Interventions
Gemcabene, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Fort Payne, Alabama • Tucson, Arizona • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

NCT05694260
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Method of Fish Oil Administration on Patient Compliance

NCT01471366
View directory record Official record
Conditions
Adverse Effects
Interventions
Frozen capsule, Capsule with food, Capsule without food, Capsule with milk
Dietary Supplement
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 19, 2026, 11:21 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Mendelian Reverse Cholesterol Transport Study

NCT01782027
View directory record Official record
Conditions
Cholesterol, HDL, Lipid Metabolism, Inborn Errors, Tangier Disease, LCAT Deficiency, Cholesteryl Ester Transfer Protein (CETP) Deficiency
Interventions
3H-cholesterol bound to albumin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

NCT06742853
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Vermont Diabetes Information System

NCT00109369
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Information and decision support for providers and patients
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

NCT01813422
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
59
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

NCT03361501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
CaPre, Placebo
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
53
States / cities
Birmingham, Alabama • Childersburg, Alabama • Encino, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00749788
View directory record Official record
Conditions
Dyslipidemia
Interventions
JTT-302, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 19, 2026, 11:21 AM EDT
Recruiting Phase 1 Interventional

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Interventions
VERVE-102
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Dothan, Alabama • Pomona, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

NCT01554800
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis
Interventions
ACP-501
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
30 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 3 Interventional

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients

NCT00239967
View directory record Official record
Conditions
Dyslipidemia, Obesity
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Familial Partial Lipodystrophy Study

NCT02858830
View directory record Official record
Conditions
Lipodystrophy, Familial Partial
Interventions
High fat mixed meal
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 19, 2026, 11:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

NCT00630734
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Pravastatin, Darunavir, Ritonavir, Washout
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 19, 2026, 11:21 AM EDT